Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Completed Initiated Sep 27, 2016 (10 years ago)

Gildess 1.5/30

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent Drug; Ethinyl Estradiol

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Gildess 1.5/30 (norethindrone acetate, 1.5 mg and ethinyl estradiol tablets, 0.03 mg, USP), 21 count, (a) 3 blisters (NDC 0603-7606-48) and (b) 6 blisters (NDC 0603-7606-15), Rx only, Manufactured in Canada By: Patheon, Inc., Ontario, Canada L5N 7K9, Manufactured for QUALITEST PHARMACEUTICALS, USA, Huntsville, AL 35811

Affected NDCs 0603-7606-15 0603-7606-48

Compare with the code on your package — it is the most precise check available.

Drug: Estradiol

Recalling firm
Par Pharmaceutical, Inc.
NDC code
0603-7606-48
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0119-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Estradiol recalls

See all
Class II · Moderate risk

Alyacen 7/7/7

Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Ongoing Impurity / degradation Glenmark Pharmaceuticals Inc., USA NDC 68462-556-29 D-0588-2026
Class II · Moderate risk

Estradiol Gel

Defective Container; packets were found to be either empty or partially full.

Ongoing Packaging defect ANI Pharmaceuticals, Inc. NDC 70954-531-20 D-0543-2026
Class II · Moderate risk

Estradiol

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0315-2026
Class II · Moderate risk

Estradiol

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0314-2026
Class II · Moderate risk

Estradiol

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0313-2026

Other recalls by Par Pharmaceutical, Inc.

All 2016 recalls
Class II · Moderate risk

Glycopyrrolate Tablets

Failed Impurities/Degradation Specification: Presence of unknown impurity observed.

Terminated Impurity / degradation Par Pharmaceutical Inc. NDC 49884-0065-01 D-1071-2020
Class III · Low risk

PrediniSONE Tablets

Labeling: Incorrect or Missing Exp Date - An incorrect expiration date has been identified on Prednisone Tablets USP 5 mg

Terminated Labeling / mix-up Par Pharmaceutical Inc. NDC 0603-5337-31 D-1035-2020
Class III · Low risk

Frovatriptan Succinate Tablets

Labeling: Incorrect or Missing Lot and/or Exp Date: Product incorrectly labeled with an expiration date of August 2022 rather than the correct expiration date of April 2022.

Terminated Labeling / mix-up Par Pharmaceutical Inc. NDC 0603-3718-34 D-0843-2020